Skip to main content

McKesson Value Stock - Dividend - Research Selection

Mckesson

ISIN: US58155Q1031 , WKN: 893953

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. The company operates in two segments, McKesson Distribution Solutions and McKesson Technology Solutions. The McKesson Distribution Solutions segment distributes branded and generic pharmaceutical drugs, and other healthcare-related products; and provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices. This segment also provides specialty pharmaceutical solutions for pharmaceutical manufacturers; and medical-surgical supply distribution, logistics, and other services to healthcare providers. In addition, this segment operates retail pharmacy chains in Europe and Canada, as well as supports independent pharmacy networks in North America and Europe; and supplies integrated pharmacy management systems, automated dispensing systems, and related services to retail, outpatient, central fill, specialty, and mail order pharmacies. This segment serves retail national accounts, including national and regional chains, food/drug combinations, mail order pharmacies, and mass merchandisers; and institutional healthcare providers, such as hospitals, health systems, integrated delivery networks, and long-term care providers, as well as offers its services to pharmaceutical manufacturers. The McKesson Technology Solutions segment provides clinical, financial, and supply chain management solutions to healthcare organizations. McKesson Corporation was founded in 1833 and is headquartered in San Francisco, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Allspring Large Cap Growth Fund Q2 2026 Performance Update

2026-08-14

AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?

2026-08-11
AbbVie commands a premium valuation for its specialty drug pipeline, while CVS Health trades at a discount despite managing 37 million medical members.

Cardinal Health Q4 Earnings Call Highlights

2026-08-11
Cardinal Health (NYSE:CAH) reported fourth-quarter fiscal 2026 results marked by growth in revenue, operating earnings and adjusted earnings per share, supported by demand in its pharmaceutical and specialty businesses and a one-time tariff-related benefit in its medical products segment. For the q

S&P 500 Medical Stocks: Three Trade Near Buy Points; One Rallies Despite Mixed Results

2026-08-11
S&P 500 drug distributor Cardinal Health easily topped fiscal fourth-quarter earnings forecasts despite a revenue shortfall. Rival McKesson, which whipsawed after its earnings report last week, has climbed back near a buy point. Cencora, another big S&P 500 drug distributor, also is near a buy point, but MCK stock may be the strongest of the three.

Wells Fargo Maintains Equal-Weight on McKesson, Raises Price Target to $933

2026-08-11
Wells Fargo analyst Stephen Baxter maintains McKesson (NYSE:MCK) with a Equal-Weight and raises the price target from $812 to $933.

QDEL Q2 Earnings & Revenues Beat Estimates, 2026 Guidance Lowered

2026-08-10
QuidelOrtho beats Q2 earnings and revenue estimates, but cuts its 2026 outlook on persistent China weakness and a softer respiratory testing environment.

Integer Holdings Q2 Earnings & Revenues Top Estimates, Margins Decline

2026-08-10
ITGR beats Q2 earnings and revenue estimates, but sales and margins decrease as product headwinds persist ahead of its $5.7B KKR deal.

McKesson Q1 Earnings Call Highlights

2026-08-08
McKesson (NYSE:MCK) reported fiscal first-quarter 2027 results that exceeded its expectations, citing broad-based momentum across its operating businesses and prompting the healthcare services company to raise its full-year adjusted earnings outlook. Revenue rose 8% to $105.4 billion, while adjuste

Dividend Announcements: July 18-24, 2026

2026-08-08
Weekly dividend stock update: 24 hikes, 1 cut. Read to see top raises like FIX & MCK, HON’s spinoff impact, and how to spot safe income.

How Higher Sales, Lower EPS And New Guidance At McKesson (MCK) Has Changed Its Investment Story

2026-08-08
On August 5, 2026, McKesson Corporation reported first-quarter fiscal 2027 results showing sales of US$105.38 billion, higher than a year earlier, while net income and earnings per share from continuing operations declined year-on-year. Alongside these results, McKesson completed a large portion of its long-running share repurchase program and raised adjusted earnings guidance, highlighting management’s confidence in specialty and oncology growth, technology and AI investments, and the...